Jan Cederholm

TL;DR: The results were comparable to data obtained with more complicated techniques, such as the insulin clamp and suppression tests, and should be easy to apply on a large scale in epidemiological studies.

TL;DR: Reducing mean HbA(1c) and BP levels and the wider use of lipid-lowering drugs during the late 1990s in patients with diabetes in a national sample from Sweden should translate into clinical benefits regarding micro- and macrovascular complications as well as diabetes-related mortality.

TL;DR: Both overweight and obesity independently increased the risk of CHD and cardiovascular disease in patients with type 2 diabetes, and the CHD risk was higher with increasing BMI than with stable or decreasing BMI during the study.

TL;DR: Metformin showed lower risk than insulin for CVD and all-cause mortality and slightly lower risk for all- cause mortality compared with other OHA, in these 51 675 patients followed for 4 years, and the benefits of metformin use clearly outbalance the risk of severe side effects.

TL;DR: Among people with type 1 diabetes use of insulin pump therapy is associated with lower cardiovascular mortality than treatment with multiple daily insulin injections, and significantly lower hazard ratios for fatal cardiovascular disease.